A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Eribulin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational
- Sponsors Eisai Inc
- 20 Aug 2024 Planned End Date changed from 31 Dec 2023 to 31 Oct 2024.
- 15 Aug 2023 Primary endpoints have been amended in the study protocol.
- 15 Aug 2023 Planned End Date changed from 30 Sep 2022 to 31 Dec 2023.